Literature DB >> 14738676

Plasma ghrelin concentratin in the short-term following biliopancreatic diversion.

Gian Franco Adami1, Renzo Cordera, Guiseppe Marinari, Giovanni Lamerini, Gabriella Andraghetti, Nicola Scopinaro.   

Abstract

BACKGROUND: Ghrelin is a hormone that increases food intake in rodents and in humans. After gastric bypass surgery, a marked decrease in circulating ghrelin levels has been observed, and it was suggested that this may contribute to the weight-reducing effect of gastric bypass. In this study, the changes in circulating ghrelin levels following biliopancreatic diversion (BPD) were investigated.
MATERIALS AND METHODS: Serum ghrelin concentration was measured in obese patients prior to and 5 days and 2 months following BPD.
RESULTS: At the short-term following BPD, marked reduction of serum ghrelin was observed, while thereafter the values returned to initial levels.
CONCLUSION: Unlike following reducing diet or gastric bypass, following BPD only an initial reduction of serum ghrelin concentration was observed, while at 2 months following the operation, when food intake had nearly completely resumed, the values returned to the preoperative levels. This is consistent with the hypothesis that ghrelin production from the stomach is greatly influenced by the direct contact of ingested food with the gastric cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14738676     DOI: 10.1381/096089203322618713

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  16 in total

Review 1.  Morbid obesity and sleeve gastrectomy: how does it work?

Authors:  Joanna Papailiou; Konstantinos Albanopoulos; Konstantinos G Toutouzas; Christos Tsigris; Nikolaos Nikiteas; George Zografos
Journal:  Obes Surg       Date:  2010-10       Impact factor: 4.129

2.  Sleeve gastrectomy model in Wistar rats.

Authors:  João de Bona Castelan; Jane Bettiol; Armando José d'Acampora; João Vicente Edom Castelan; Jonathan Caon de Souza; Vinicius Bressiani; Simone Batisti Giroldi
Journal:  Obes Surg       Date:  2007-07       Impact factor: 4.129

3.  Laparoscopic sleeve gastrectomy with ileal transposition (SGIT): A new surgical procedure as effective as gastric bypass for weight control in a porcine model.

Authors:  Camilo Boza; Michel Gagner; Nicolás Devaud; Alex Escalona; Rodrigo Muñoz; Monica Gandarillas
Journal:  Surg Endosc       Date:  2008-02-13       Impact factor: 4.584

Review 4.  Obesity, gut hormones, and bariatric surgery.

Authors:  Dimitrios J Pournaras; Carel W le Roux
Journal:  World J Surg       Date:  2009-10       Impact factor: 3.352

5.  Effects of two variants of Roux-en-Y Gastric bypass on metabolism behaviour: focus on plasma ghrelin concentrations over a 2-year follow-up.

Authors:  Noelia Pérez-Romero; Assumpta Serra; Maria Luisa Granada; Miquel Rull; Antonio Alastrué; Maruja Navarro-Díaz; Ramón Romero; Jaime Fernández-Llamazares
Journal:  Obes Surg       Date:  2009-12-17       Impact factor: 4.129

Review 6.  Could the improvement of obesity-related co-morbidities depend on modified gut hormones secretion?

Authors:  Carmine Finelli; Maria Carmela Padula; Giuseppe Martelli; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

Review 7.  Changes in neurohormonal gut peptides following bariatric surgery.

Authors:  C N Ochner; C Gibson; M Shanik; V Goel; A Geliebter
Journal:  Int J Obes (Lond)       Date:  2010-07-13       Impact factor: 5.095

Review 8.  Gastrointestinal changes after bariatric surgery.

Authors:  I Quercia; R Dutia; D P Kotler; S Belsley; B Laferrère
Journal:  Diabetes Metab       Date:  2013-12-17       Impact factor: 6.041

9.  Ghrelin and metabolic surgery.

Authors:  Dimitrios J Pournaras; Carel W le Roux
Journal:  Int J Pept       Date:  2010-01-27

Review 10.  Pathophysiology of obesity: why surgery remains the most effective treatment.

Authors:  Talat Waseem; Kris M Mogensen; David B Lautz; Malcolm K Robinson
Journal:  Obes Surg       Date:  2007-10       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.